Antibodies have a charge problem. That’s the finding underneath a piece of research from the University of Essex, and it explains why decades of antibody work has mostly stopped at the cell membrane.
Working with an international team, the Essex scientists used artificial intelligence to build extremely small antibody fragments that can be produced directly inside human cells. Once inside, the fragments can attach to proteins associated with disease.
Ordinary antibodies generally work outside cells. The redesigned fragments, called intrabodies, are engineered to stay stable within cells instead, which puts them in reach of the proteins involved in neurodegenerative conditions.
Charge, not shape, was the blocker
The work was funded by the MND Association and led by Dr. Caitlin O’Shea and Dr. Gareth Wright of the School of Life Sciences. What the team found is that electrical charge is a key factor in whether an antibody fragment stays stable and functional inside a cell.
Pair that insight with AI-driven protein redesign and you get numbers rather than promises. The researchers converted 672 different antibodies into intrabodies capable of targeting important disease-related proteins.
The approach could give scientists new ways to study and potentially treat neurodegenerative diseases by acting directly inside living cells, where many of the biological processes behind these conditions begin.
After publication in Nature Communications, the redesigned molecules will be made freely available to other scientists. That last detail matters more than it sounds. Freely available means other labs can test the claim rather than take it on faith.
How they figured it out
O’Shea, the lead author, specializes in MND and Parkinson’s disease. She said: “We looked at the properties of millions of antibodies and compared them with human proteins found inside the cell.
“From this we figured out that antibodies usually have the wrong charge to exist inside cells without sticking together.
“We used software developed by Nobel Prize winner David Baker and his group to redesign our antibody fragments, so they had the right charge and are super stable.”
Millions of old antibodies, potentially new jobs
The researchers think the findings could let scientists find new uses for millions of antibodies developed over decades of biomedical research.
Instead of starting from scratch, existing antibodies may be adaptable into laboratory tools and, potentially, the foundation for future treatments aimed at disease-causing proteins. Potentially is doing real work in that sentence, and the researchers don’t pretend otherwise.
Wright, who directed the research, said the approach could have major implications for diseases affecting tens of millions of people worldwide.
“We’ve made intracellular antibodies that stick to proteins that cause neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s and motor neurone disease,” said Wright.
“These diseases can lead to cognitive impairment, forgetfulness, loss of muscle control and death. They affect over one million people in the UK alone, so they are a big public health concern.
“There are no cures for these diseases and finding molecules that interact with the proteins that cause them in their native environment is a major challenge in the medicine discovery process.”
What the funder says, and what it doesn’t
The MND Association welcomed the findings and pointed to their possible importance for future treatments. Read the charity’s language closely and you’ll notice how carefully hedged it is.
Dr. Brian Dickie, chief scientist at the charity, said: “Dr. Wright and his colleagues have made a significant advance in overcoming one of the key challenges that has impeded the development of antibodies as treatments for neurodegenerative diseases, such as MND.
“Their research findings provide optimism that a combination of this novel ‘intrabody’ science with emerging gene therapy techniques may lead to new therapeutic strategies that can hit specific molecular targets within neurones.”
May lead. Emerging gene therapy techniques. Those are the load-bearing qualifiers, and they’re the honest ones. Nobody here is claiming a treatment.
If you want a single number to hold onto from this work, make it 672. That’s how many antibodies made the jump from outside the cell to inside it, and every one of them is about to land in other researchers’ hands.
